Sarfez Pharmaceuticals, Inc.
A study Comparing the Clinical Benefit of Finerenone Versus a Fixed-Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients with Hypertension and Chronic Kidney Disease.
SAR-ERTSP-01P, A Randomized, Parallel, Two-Arm Study Comparing the Net Clinical Benefit of Finerenone Versus a Fixed-Dose Combination of Extended-Release Torsemide and Spironolactone in Patients with Hypertension and PRoteinuric ChrOnic KidNey Disease (NEPHRON).
Inclusion Criteria: 1. Adult male and female patients aged ≥18 years; 2. Are diagnosed with a CKD; 3. Have an eGFR of ≥25 and ≤60 mL/min/1.72 m2; 4. Have an UACR 150-3500 mg/g and Sk 4.5 to 5.0 mmol/L; 5. Have an observed clinic seated systolic blood pressure (SBP) of ≥130 and ≤170 mmHg; 6. Are receiving up to an 80 mg daily dose of furosemide or an equivalent dose of other loop diuretics and and 10 mg daily dose of finerenone for 30 days; 7. Willing and able to comply with all aspects of the protocol and to provide written informed consent from the patient or patient's legally acceptable rep…
The usual starting torsemide daily dose ranges from 5-10 mg (for hypertension) to 10-20 mg (for heart failure). The initial dose for treatment of heart failure or hypertension is 25 mg daily.
Treatment will be up to 80 mg furosemide or equivalent doses of other loop diuretics and 10 mg finerenone
Arctuva estimate
Verify or correct the compensation shown for this listing.